Bone Therapeutics Ipo Adviser

Bone therapeutics ipo adviser

Bone therapeutics ipo adviser

Sanford J. Madigan, Ph.D.
CEO, Ankasa Regenerative Therapeutics

Sandy is the founding CEO of Ankasa, for which he raised a $19M financing to support the Company’s efforts to bring a recombinant WNT-based therapeutic into clinical development for various orthopedic applications.

Bone therapeutics ipo adviser

He brings over 25 years of industry experience to this role and is experienced in venture financings, licensing founding and value-added technologies, and negotiating strategic partnerships and corporate acquisitions.

Sandy was the transacting CEO of Calporta Therapeutics which was acquired by Merck in November, 2019 for up to $576M including an upfront payment and contingent milestone payments. In addition to Calporta, Sandy has been a founder and senior manager in various venture-backed organizations including Anexigen, Inc.

(partnered with major pharma), Sova Pharmaceuticals, Strategic Enzyme Applications (partnered with Monsanto), Ambit Biosciences (IPO, acquired by Daiichi Sankyo), Xenopharm (acquired by Deltagen), X-Ceptor Therapeutics (acquired by Exelixis), and SIBIA Neurosciences (acquired by Merck).

Bone Therapeutics - pharma.be - Dialogue 2018